News December 2013 Issue

In The News: December 2013

The Food and Drug Administration (FDA) has approved ustekinumab (Stelara®), alone or in combination with methotrexate, for the treatment of adult patients (18 years of age or older) with active psoriatic arthritis. Administered as a 45-mg subcutaneous (SC) injection, ustekinumab is given at weeks zero and four, and then every 12 weeks thereafter.

To continue reading this article you must be a paid subscriber.

Subscribe to Arthritis Advisor

Arthritis Advisor is the first magazine published by one one of the world's leading orthopaedic hospitals specifically for people with arthritis.

Subscriber Log In

Forgot your password? Click Here.

Already subscribe but haven't registered for all the benefits of the website? Click here.